Sleep and Respiratory Network Interaction in ALS — Experiment Design

Experiment Overview

This experiment addresses ALS Knowledge Gap #18 (Score: 26/40): "How do sleep and respiratory-control networks interact with neurodegenerative progression rather than late-stage disability alone?" The gap emphasizes that sleep and respiratory dysfunction are often treated as late-stage issues, but they may be early biomarkers and therapeutic targets.

Related: [ALS Knowledge Gaps](/gaps/als) | [Sleep-Circadian Neurodegeneration](/mechanisms/sleep-circadian-neurodegeneration) | [ALS Cure Roadmap](/therapeutics/als-cure-roadmap)

Background and Rationale

Sleep Dysfunction in ALS

High prevalence: 50-75% of ALS patients report significant sleep disturbances, often beginning early in disease course[@sleep2023]

Multiple causes: Sleep fragmentation from nocturnal hypoventilation, muscle cramps, anxiety, and central circadian disruption

Impact: Sleep quality strongly correlates with quality of life, daytime fatigue, and may accelerate disease progression

Respiratory Dysfunction

Early involvement: Respiratory motor neurons (phrenic nucleus, accessory respiratory neurons) are affected early

Nocturnal hypoventilation: Often precedes daytime respiratory failure by months to years[@als2024]

REM sleep vulnerability: Loss of accessory muscle tone during REM leads to hypoventilation

Circadian Disruption

...

Experiment Overview

This experiment addresses ALS Knowledge Gap #18 (Score: 26/40): "How do sleep and respiratory-control networks interact with neurodegenerative progression rather than late-stage disability alone?" The gap emphasizes that sleep and respiratory dysfunction are often treated as late-stage issues, but they may be early biomarkers and therapeutic targets.

Related: [ALS Knowledge Gaps](/gaps/als) | [Sleep-Circadian Neurodegeneration](/mechanisms/sleep-circadian-neurodegeneration) | [ALS Cure Roadmap](/therapeutics/als-cure-roadmap)

Background and Rationale

Sleep Dysfunction in ALS

High prevalence: 50-75% of ALS patients report significant sleep disturbances, often beginning early in disease course[@sleep2023]

Multiple causes: Sleep fragmentation from nocturnal hypoventilation, muscle cramps, anxiety, and central circadian disruption

Impact: Sleep quality strongly correlates with quality of life, daytime fatigue, and may accelerate disease progression

Respiratory Dysfunction

Early involvement: Respiratory motor neurons (phrenic nucleus, accessory respiratory neurons) are affected early

Nocturnal hypoventilation: Often precedes daytime respiratory failure by months to years[@als2024]

REM sleep vulnerability: Loss of accessory muscle tone during REM leads to hypoventilation

Circadian Disruption

Altered rhythms: ALS patients show disrupted circadian rhythms of cortisol, melatonin, and body temperature[@circadian2023]

Biomarker potential: Circadian disruption may be an early marker of brainstem involvement

Therapeutic opportunity: Sleep optimization may improve overall disease trajectory

Study Design

Type

Prospective, longitudinal cohort with continuous monitoring

Hypotheses

Primary Hypothesis: Sleep and respiratory metrics collected early in ALS (within 6 months of diagnosis) predict disease progression rate and survival, independent of established clinical measures.

Secondary Hypotheses:

• Early detection and treatment of sleep-disordered breathing improves progression trajectory
• Circadian disruption correlates with specific motor neuron involvement patterns
• Sleep architecture changes precede measurable respiratory decline

Population

| Parameter | Value |
|-----------|-------|
| Newly diagnosed ALS | 200 |
| Follow-up | 24 months |
| Polysomnography capacity | 100 (subset) |

Inclusion Criteria

Diagnosis of clinically definite or probable ALS ≤6 months

Disease duration ≤12 months from symptom onset

Able to perform sleep study (no severe respiratory failure)

Willing to use home sleep monitoring device

Assessments

Baseline

| Assessment | Purpose |
|------------|---------|
| Polysomnography (subset, n=100) | Detailed sleep architecture |
| Home sleep apnea test (all) | Respiratory events during sleep |
| Actigraphy (2 weeks) | Circadian rhythm patterns |
| Overnight oximetry + capnography | Nocturnal hypoventilation |
| ALSFRS-R, ALSFRS-R slope | Baseline severity |
| Forced vital capacity | Respiratory function |
| Sleep questionnaires | ESS, PSQI, AIS |

Longitudinal (Every 6 Months)

| Assessment | Timepoints |
|------------|------------|
| ALSFRS-R | Baseline, 3, 6, 12, 18, 24 months |
| FVC, MIP, MEP | Baseline, 6, 12, 24 months |
| Overnight oximetry | Baseline, 3, 6, 12, 18, 24 months |
| Actigraphy | 2-week periods at each timepoint |

Advanced Sub-study (n=50)

• Longitudinal polysomnography at baseline, 12, 24 months
• CSF for circadian-related biomarkers (melatonin, orexin)
• Brainstem auditory evoked potentials

Sleep-Disordered Breathing Intervention

Rationale

If early sleep-disordered breathing predicts progression, test whether early intervention improves outcomes:

Design: Randomized, controlled (comparing early vs delayed NIV) Population: ALS patients with nocturnal hypoventilation but FVC >50% predicted n: 80 (40 early intervention, 40 delayed) Duration: 12 months Endpoints:

• ALSFRS-R trajectory
• FVC decline rate
• Sleep quality metrics
• Quality of life

Biomarker Analysis

Sleep-Based Predictors

| Marker | Measurement | Predictive Value |
|--------|-------------|------------------|
| AHI (apnea-hypopnea index) | PSG | Progression rate |
| Nocturnal O2 nadir | Oximetry | Survival |
| Sleep efficiency | PSG | Quality of life |
| REM latency | PSG | Disease subtype |
| Circadian amplitude | Actigraphy | Brainstem involvement |

Statistical Models

Cox proportional hazards: Survival ~ baseline sleep metrics + covariates

Linear mixed models: ALSFRS-R trajectory ~ sleep metrics × time

Machine learning: Random forest for progression prediction using sleep features

Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Impact | 7 | Reveals interaction between sleep networks and motor neuron degeneration |
| Cure Proximity | 5 | Sleep optimization improves quality but unlikely to cure |
| Feasibility | 7 | Home monitoring feasible; PSG in subset |
| Cost Efficiency | 7 | Relatively low-cost monitoring with high predictive value |
| Timeline | 8 | 24-month follow-up; predictive models within 12 months |
| Cross-Disease Value | 8 | Sleep-respiratory interaction relevant to PD, MSA |
| Biomarker Enablement | 9 | Sleep metrics may be early biomarkers of progression |
| Combinability | 7 | Can combine with respiratory support and neuroprotective therapies |
| De-risking Value | 7 | Early intervention trials can be designed based on findings |
| Novelty | 8 | Focus on early detection rather than late-stage management |

Total: 73/100

Expected Outcomes

Sleep metrics predict progression: Specific patterns (e.g., early REM hypoventilation) correlate with fast progression → implement early screening

Early NIV improves outcomes: Early intervention slows progression → change standard of care

Circadian biomarkers: Disruption correlates with brainstem involvement → new biomarker development

Negative/Neutral: No predictive value → focus remains on motor measures

References

[Boentert et al., Sleep-disordered breathing in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38561234/)

[Choudhuri et al., Sleep disturbances in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Patrone et al., Circadian rhythm disruption in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Kleopa et al., Respiratory motor neuron vulnerability (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

Pathway Diagram

The following diagram shows key molecular relationships for Sleep and Respiratory Network Interaction in ALS — Experiment Design based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving Sleep and Respiratory Network Interaction in ALS — Experiment Design discovered through SciDEX knowledge graph analysis: